Archived explainer. For the current picture see today's KNSA page.
KINIKSA PHARMACEUTIC A (KNSA) is up +25.03% in the latest session. Our newswire has captured 10 stories on KNSA across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100).
KNSA stock rose 25.03% to $79.44 on Monday, driven by strong second-quarter results and an upward revision to 2026 revenue guidance. Kiniksa Pharmaceuticals reported a 55% year-over-year increase in ARCALYST sales, with the drug generating $243.6 million in revenue for the quarter. The company also raised its 2026 revenue guidance to $980 million to $995 million and advanced its KPL-387 candidate into a pivotal Phase III trial for recurrent pericarditis.
Kiniksa’s Q2 2026 earnings call highlighted significant progress across its business and pipeline. ARCALYST, the company’s flagship drug, delivered a major revenue leap, contributing to the raised full-year guidance. The company also announced the initiation of the Phase III PASTORALE trial for KPL-387, a development that signals continued momentum in its therapeutic pipeline. The SEC 8-K filing on July 28 confirmed the results of operations and financial condition, further validating the company’s performance. GAAP earnings per share of $0.30 exceeded estimates by $0.01, and total revenue beat expectations by $17.14 million.
The stock has gained 23.7% over the past eight sessions, moving from $63.95 to $79.14. With a market cap of $4.8 billion, the company trades at a P/E ratio of 70.0, reflecting a premium valuation. Kiniksa’s trailing twelve-month revenue growth is 56.7%, and its net margin stands at 9.7%. The recent earnings beat and guidance raise have likely contributed to increased investor confidence, with the stock trading well above its 52-week range of $26.27 to $67.53.
The company is not scheduled to report earnings in the near term, but coverage breadth will be a key metric to monitor. With 10 stories from six sources in the last 36 hours, investor sentiment and media attention are intensifying around Kiniksa’s performance and pipeline developments.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Kiniksa Pharmaceuticals delivers a robust Q2 2026, with a major leap in ARCALYST revenue, boosted financial guidance, and clinical progress across its pipeline. We dissect the key figures and strategic portfolio moves driving optimism for KNSA.
Kiniksa (KNSA) Q2 2026 earnings call: ARCALYST sales up 55%, guidance raised to $980M–$995M, and KPL-387 Phase III launch.
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call July 28, 2026 8:30 AM EDTCompany ParticipantsJonathan Kirshenbaum - Investor...
Kiniksa reported strong Q2 2026 earnings, raised ARCALYST sales guidance to $980-$995 million, and advanced KPL-387 into a pivotal Phase 3 trial for recurrent pericarditis.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) reported second-quarter ARCALYST revenue of $243.6 million, up 55% from a year earlier and more than $29 million from the first quarter, as the company cited continued expansion in both new and repeat prescribers for the recurrent pericarditis trea
Kiniksa Pharmaceuticals raised its 2026 ARCALYST revenue guidance on the back of robust Q2 results and accelerating clinical progress. The company’s lead asset, ARCALYST, delivered 55% year-over-year net product revenue growth while next-in-line KPL-387 advanced into Phase 3—positioning Kiniksa as a key player in rare cardiovascular disease treatments.
Kiniksa (KNSA) Q2 earnings: GAAP EPS beat, revenue up 55% on ARCALYST.
Filed: 2026-07-28 AccNo: 0001730430-26-000031 Size: 368 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
More on KNSA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier KNSA move explainers: 2026-07-29 · 2026-07-28